SEC Form 4 · accession 0000874015-26-000254
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Hayden
Director
Period of report
Jul 30, 2026
Accepted (ET)
Jul 31, 2026 · 4:42 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 30, 2026 | P | 15,000 | $53.38 | A | 19,000 | I | by Spouse |
| Common StockF3,F2 | Jul 31, 2026 | P | 5,000 | $51.60 | A | 24,000 | I | by Spouse |
| Common Stock | holding | — | — | — | 54,298 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.
- F2These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2.
- F3The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) on this Form 4.